Similar articles

• The OPTIMAAL study, not so optimal: the lessons of LIFE, RENAAL and IDNT.

  Lapointe N, Pourdjabbar A, Rouleau JL. Lapointe N, et al. Can J Cardiol. 2003 Aug;19(9):994-6. Can J Cardiol. 2003. PMID: 12915925 No abstract available.
• Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy.

  Møller JE, Dahlström U, Gøtzsche O, Lahiri A, Skagen K, Andersen GS, Egstrup K; OPTIMAAL Study Group. Møller JE, et al. Am Heart J. 2004 Mar;147(3):494-501. doi: 10.1016/j.ahj.2003.10.031. Am Heart J. 2004. PMID: 14999200 Clinical Trial.
• What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?

  Dickstein K. Dickstein K. Am Heart J. 2003 May;145(5):754-7. doi: 10.1016/S0002-8703(03)00168-6. Am Heart J. 2003. PMID: 12766730 No abstract available.
• The use of angiotensin converting enzyme inhibitors in asymptomatic patients with left ventricular dysfunction after myocardial infarction.

  Bazunga M. Bazunga M. Conn Med. 1995 Nov;59(11):663-6. Conn Med. 1995. PMID: 8565511 Review. No abstract available.
• [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].

  Ferrari R, Papa K, Bernocchi P, Gimbatti OJ, Golcea SS, Bettini A, Ceconi C. Ferrari R, et al. Ital Heart J. 2005 Nov;6 Suppl 7:24S-32S. Ital Heart J. 2005. PMID: 16485514 Review. Italian.